Novel influenza inhibitors designed to target PB1 interactions with host importin RanBP5

Antiviral Res. 2019 Apr:164:81-90. doi: 10.1016/j.antiviral.2019.02.003. Epub 2019 Feb 8.

Abstract

In search of novel targets for influenza inhibitors, a site on PB1 was selected for its high conservation and probable interaction with a host protein, RanBP5, that is key to nuclear import of PB1, where it complexes with PB2, PA, and NP to transcribe viral RNA. Docking with libraries of drug-like compounds led to a selection of five candidates that bound tightly and with a pose likely to inhibit protein binding. These were purchased and tested in vitro, found to be active, and then one was synthetically expanded to explore the structure-activity relationship. The top candidates had a carboxylic acid converted to an ester and electron-withdrawing substituents added to a phenyl group in the original structure. Resistance was slow to develop, but cytotoxicity was moderately high. Nuclear localization of PB1 and in vitro polymerase activity were both strongly inhibited.

Keywords: Antiviral; Nuclear localization; Polymerase inhibition; Virtual screening.

MeSH terms

  • Computer Simulation
  • Drug Discovery
  • High-Throughput Screening Assays
  • Humans
  • Influenza A virus / drug effects*
  • Influenza A virus / enzymology
  • Influenza, Human / drug therapy*
  • Molecular Docking Simulation
  • Structure-Activity Relationship
  • Viral Proteins / antagonists & inhibitors*
  • Virus Replication / drug effects
  • beta Karyopherins / metabolism*

Substances

  • IPO5 protein, human
  • Viral Proteins
  • beta Karyopherins
  • influenza virus polymerase basic protein 1